From Conference to Practice: Big Data in Psoriasis

This program will include a discussion of investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Description of Program

Description of Program

Comorbid Diseases Associated With Psoriasis

Psoriasis Is a Chronic, Systemic, Inflammatory Disease

Cardiovascular Disease

Atherosclerotic Disease and Psoriasis

Joint Disease

Treatments for Psoriatic Arthritis

Summary

Updates on Topical Therapies

Halobetasol (0.01%)/Tazarotene (0.04%): Phase 3 Studies

Halobetasol (0.01%)/Tazarotene (0.04%): Efficacy Data

Tapinarof: Phase 2 Study

Tapinarof Phase 2 Study: Efficacy Data

Tofacitinib Topical: Phase 2 Study

Tofacitinib Topical Phase 2 Study: Efficacy Data

Implications for Practice

What’s New in Oral Therapies

Considerations Regarding Oral Therapies

Apremilast: Long-term Efficacy in Skin Disease

Apremilast: Efficacy in Nail Disease

Tofacitinib: Efficacy in Nail Psoriasis

Tofacitinib: NAPSI Scores at Week 52

New Data on TNF Inhibitors

Long-term Safety and Efficacy of Adalimumab: ESPIRIT Registry

Adalimumab Efficacy: PGA 1/0

Certolizumab Pegol

Certolizumab Pegol: Efficacy Data

TNF Inhibitors and Pregnancy

Updates on IL-17 Blockers

The New Gold Standard

Secukinumab: Long-term Efficacy

Ixekizumab: Long-term Efficacy

Brodalumab: Long-term Efficacy

IL-17 Blockers Are a “Game-Changer”

Emerging Data on IL-23 Inhibitors

IL-23 in Psoriasis

Guselkumab: Phase 3 Efficacy Data

Risankizumab: Phase 2 Efficacy Data

Tildrakizumab: 2-Year Open-label Extension

Implications for Practice

Abbreviations

Abbreviations (cont)